This research study is comparing the effects of the study drug KPI-121 to a drug already on the market in treating the signs and symptoms of inflammation in the eye immediately after cataract surgery. The new drug is only given twice a day compared to the marketed drug which is given four times a day for routine uncomplicated cataract surgery. Study participation will last 6 weeks and require 6 study visits, including screening visit.
The purpose of this study is to understand better how many people who have been diagnosed with early-onset idiopathic bilateral cataracts may have a rare but treatable disease called Cerebrotendinous Xanthomatosis (CTX)
We propose a prospective observational analysis of near visual acuity and stereopsis in pseudophakic children. Visual acuity analysis will be standardized based on age per PEDIG protocols. Results will be stratified by age and by monocular versus binocular surgery. Children will be assessed in their appropriate corrective lenses to control for myopia as a confounding factor. Refractive error will be measured to optimize visual acuity measurement and assess for the potential role of astigmatism in preservation of near visual function.